Matthew Herper covers medical innovation — both its promise and its perils. It has been a tough year for medicine. The U.S.

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics ( NTLA ) ...

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of ...

Tucked inside a 3,000-page national defense bill signed into law last month is a set of new regulations that could upend the way local biotech companies do business. The Biosecure Act, as it is known, ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

In The Star's annual year in review, the county's biggest business stories included housing proposals and the aftermath of a ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

The new saw: Development-stage biotechs are maturing. Their drugs are winning approvals and independent commercial launches are starting to deliver meaningful revenue. The sector is turning profitable ...

Here is the full list of the biotech and pharma Startup Battlefield 200 selectees, along with a note on what made us select ...

According to Gartner, 58% of finance functions employed AI in 2024—a 21-percentage-point jump from the prior year. PwC ...

Boston spent the past decade selling itself as the safest bet in science, a place where a doctorate was practically a ticket ...

O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...